A Prospective, Open, Multicenter Clinical Observational Study of Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma
80% of patients with mantle cell lymphoma (mantle cell lymphoma, MCL)were in the advanced tumor stage when they were first diagnosed. Zabutinib, as a new generation of BTK inhibitors, has better targeting and safety in clinical application. Previous studies have confirmed that zabutinib has good efficacy in treating relapsed refractory MCL. However, for patients with a high risk of drug resistance to BTK inhibitors or patients with drug resistance, the efficacy of BTK inhibitors alone is poor, and combined therapy can improve the poor prognosis of these patients. Therefore, the primary purpose of this study is to evaluate the safety and efficacy of zebutenil in treating recurrent, refractory mantle cell lymphoma.
• Patients who have been enrolled in other clinical trials.
• Patients who are receiving immunosuppressive therapy for other diseases.
• Patients who have received other treatments for lymphoma before joining the group.
• Complicated with other malignant tumors.
• The researchers determined that the patients were not suitable for the study.
• Severe mental or neurological disorders that affect informed consent or expression of adverse reactions.
• Patients who cannot be followed up.